This trial is evaluating whether Next Generation Sequencing will improve 1 primary outcome and 6 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of After treatment, day 15.
This trial requires 20 total participants across 1 different treatment group
This trial involves a single treatment. Next Generation Sequencing is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.
"Recent findings indicate that the frequency of bone marrow involvement increases with time after diagnosis of myeloma. However, these results need to be taken cautiously because most patients enrolled In a recent study were enrolled within 1 year of diagnosis. In addition, all patients were treated in one institution, so generalizability of these findings cannot be assumed." - Anonymous Online Contributor
"The median number of changes detected was 2.5 (range 0–39). 18% of patients had ≥3 copy number changes, and 12% had ≥9 copy number alterations. Most common changes were recurrent gains of 1q21.1, 5q34, 8q24.1, 9p13.33-p24.1, 15q11.2-q13, 20q12.1, Xp11.22, Xp11.23, Xq21.1 and XXY. Receipt of lenalidomide plus dexamethasone significantly reduced the rate of progression compared with standard therapy alone." - Anonymous Online Contributor
"Recent findings suggest that MM does not necessarily have to be inherently lethal. Instead, it appears to be more likely to be incurable if the disease progresses quickly." - Anonymous Online Contributor
"NGS is an effective tool to discover novel genetic mutations associated with MM/CLL. Data from a recent study sheds light on the evolution of this disease, which will help us understand its pathogenesis and development." - Anonymous Online Contributor
"NGS is a powerful tool for identifying specific mutations. However, it also generates ordering information on somatic mutations and the frequency of these mutations. The issue of the 'trivial' variants needs more attention in future research. More importantly, it is important to consider the potential significance of the variants identified in patients with MM." - Anonymous Online Contributor
"There is no good evidence supporting any particular risk factors for clinical trial enrollment in MM, other than age>or=65. Clinical trial enrollment criteria must be specified so that patients with more favorable baseline characteristics will enroll in trials. The two most important factors were an excellent performance status and low levels of bone marrow suppression during induction therapy." - Anonymous Online Contributor
"Multiple myeloma has two major subgroups, one with a very good prognosis (PFS >30 months) and another where PFS is <6 months and OS <9 months. The difference could be due to differences in treatments. Recent findings support the use of more intensive therapies in patients who are at higher risk of relapse or progression. Recent findings of our analysis suggest that there is a group of patients who may benefit from such a strategy." - Anonymous Online Contributor
"About one in twenty Americans will develop multiple myeloma every year; however, only 1 out of 5 will survive at least five years after diagnosis. Multiple myeloma occurs between age 70 and 80. The overall amount of new cases diagnosed each year is about 900 per million population. As many as 90% of newly diagnosed patients will die within 5 years." - Anonymous Online Contributor
"I am sorry to tell you that multiple myeloma cannot be cured; however, current treatments for this cancer have improved the chances of survival when compared to 5 years ago. In addition, improvements have been seen in the ability to control blood cell production, which in turn has significantly improved overall survival rates. Multiple myeloma is an incurable disease that requires ongoing clinical trials and supportive care. So far, some of the most effective treatments include autologous stem cell transplantation, bortezomib, thalidomide, lenalidomide, and proteasome inhibitors." - Anonymous Online Contributor
"Most patients with MDS are treated with different combinations of agents used to treat hematological malignancies including tyrosine kinase inhibitors (including imatinib), alkylating agents (including temozolomide), and antimetabolites (which include azacitidine and decitabine). The use of NGS to identify genetic aberrations has led to the development of novel treatments for MDS. These treatments include bortezomib, lenalidomide, pomalidomide, and thalidomide. A number of studies have reported improved survival with these agents versus older treatment options." - Anonymous Online Contributor